Kevin J. Black, M.D.


Neurosciences Program
Biomedical Informatics and Data Science Program

  • 314-362-5041

  • 314-362-5041

  • 314-362-0168

  • 8134-70-2205

  • East Bldg., Rm 2205



  • fMRI, neuroimaging, movement disorders, Tourette syndrome, pharmacology, PET, deep brain stimulation, DBS

  • (1) Tourette syndrome neuroimaging; (2) Parkinson disease pharmacological imaging; (3) pharmacological activation neuroimaging

Research Abstract:

My clinical interests focus on the interface between psychiatry and movement disorders. I am especially interested in the "pre-Tourette" period in children with tics, and in Parkinson disease.

My imaging research is influenced by these clinical interests and is primarily focused on functional imaging of the dopaminergic system.

Specific projects, current and past, and my mentorship history, are summarized on the lab web page (

Selected Publications:

For a more comprehensive and up-to-date list, see my bibliography online at NLM. 

Beeler P, Jensen NO, Kim S, Robichaux-Viehoever A, Schlaggar BL, Greene DJ, *Black KJ, *Chakrabarty R: Fractality of tics as a quantitative assessment tool for Tourette syndrome. J R Soc Interface 2022; 19:20210742. PMID: 35193387. PubMed Central PMCID: PMC8864347. DOI: 10.3390/jcm9061715. PubMed PMID: 32503289; PubMed Central PMCID: PMC7355974.

Black KJ, Acevedo HK, Koller JM. Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease. Front Neurol. 2020;11:370. doi: 10.3389/fneur.2020.00370. PubMed PMID: 32477245; PubMed Central PMCID: PMC7232584.

*Greene DJ, *Williams AC III, Koller JM, Schlaggar BL, Black KJ, The Tourette Association of America Neuroimaging Consortium (2017). Brain structure in pediatric Tourette syndrome. Molecular Psychiatry 22(7):972-980. PubMed PMID: 27777415 PubMedCentral PMCID: PMC5405013 DOI: 10.1038/mp.2016.194 *Equal contributors 

Eisenstein SA, Koller JM, Black KD, Campbell MC, Lugar HM, Ushe M, Tabbal SD, Karimi M, Hershey T, Perlmutter JS, Black KJ (2014). Functional anatomy of subthalamic nucleus stimulation in Parkinson disease. Annals of Neurology 76(2): 279-295. PubMed PMID 24953991 PubMedCentral PMCID: PMC4172323 DOI: 10.1002/ana.24204 

Black KJ, Koller JM, Campbell MC, Gusnard DA, Bandak SI (2010 Dec 1). Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. Journal of Neuroscience 30(48): 16284-16292. PubMed PMID 21123574 PubMedCentral PMCID: PMC3008651 DOI: 10.1523/JNEUROSCI.2590-10.2010

Black KJ, Hershey T, Koller JM, Videen TO, Mintun MA, Price JL, Perlmutter JS: A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci U S A 2002; 99(26):17113-17118. PubMed PMID 12482941  PubMed Central PMCID 139278   DOI: 10.1073/pnas.012260599 

Last Updated: 3/31/2022 5:43:22 PM

Weighted mean image (i), p-image (ii) and 3D p-image (iii) for measures with significant effect of contact location in the 3D analyses. (a) Body bradykinesia and hypokinesia item. (b) Rigidity. (c) Tremor at rest. Fig. 2 from Gourisankar et al, 2018.
Back To Top

Follow us: